PITTSBURGH, Oct. 23, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has filed an expedited motion in the U.S. District Court for the District of Columbia to stay the Court's order related to Watson's abbreviated new drug application (ANDA) for pioglitazone, pending appeal. The U.S. Food and Drug Administration (FDA) joined Mylan in its motion.
Mylan CEO Heather Bresch commented, "Mylan is disappointed in yesterday's ruling regarding pioglitazone and we believe the Court erred in its decision by directly contravening the Hatch-Waxman Act. Mylan does not believe Watson is entitled to participate in Mylan's 180-day exclusivity period in relation to this product and we intend to pursue this case vigorously, including seeking expedited relief from the appellate court if necessary."
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.